Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors

Giulia Bononi, Carlotta Granchi, Margherita Lapillo, Massimiliano Giannotti, Daniela Nieri, Serena Fortunato, Maguie El Boustani, Isabella Caligiuri, Giulio Poli, Kathryn E. Carlson, Sung Hoon Kim, Marco Macchia, Adriano Martinelli, Flavio Rizzolio, Andrea Chicca, John A. Katzenellenbogen, Filippo Minutolo, Tiziano Tuccinardi

Research output: Contribution to journalArticlepeer-review


Monoacylglycerol lipase (MAGL) is the enzyme hydrolyzing the endocannabinoid 2-arachidonoylglycerol (2-AG) to free arachidonic acid and glycerol. Therefore, MAGL is implicated in many physiological processes involving the regulation of the endocannabinoid system and eicosanoid network. MAGL inhibition represents a potential therapeutic target for many diseases, including cancer. Nowadays, most MAGL inhibitors inhibit this enzyme by an irreversible mechanism of action, potentially leading to unwanted side effects from chronic treatment. Herein, we report the discovery of long-chain salicylketoxime derivatives as potent and reversible MAGL inhibitors. The compounds herein described are characterized by a good target selectivity for MAGL and by antiproliferative activities against a series of cancer cell lines. Finally, modeling studies suggest a reasonable hypothetical binding mode for this class of compounds.

Original languageEnglish
Pages (from-to)817-836
Number of pages20
JournalEuropean Journal of Medicinal Chemistry
Publication statusPublished - Sep 5 2018


  • Cancer
  • Ketoxime
  • MAGL
  • Monoacylglycerol lipase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors'. Together they form a unique fingerprint.

Cite this